The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States

To estimate the economic burden of systematic lupus erythematous (SLE), stratified by disease severity, in commercially- and Medicaid-insured US populations. Adults (≥18 years) with SLE treated with antimalarials, selected biologics, immunosuppressants, and systemic glucocorticoids (2010–2014) were...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in arthritis and rheumatism 2020-08, Vol.50 (4), p.759-768
Hauptverfasser:	Clarke, Ann E., Yazdany, Jinoos, Kabadi, Shaum M., Durden, Emily, Winer, Isabelle, Griffing, Kirstin, Costenbader, Karen H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Autoimmune disease Healthcare costs Healthcare utilization Medication Severity Systemic lupus erythematosus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!